Shares of Castle Biosciences (NASDAQ: CSTL) tumbled 9% after Novitas, a regional Medicare contractor, finalized its decision not to cover one of the company's cancer tests. The Novitas Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback